|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current evidence on potential of adipose derived stem cells to enhance bone regeneration and future projection显示文摘Injuries to the postnatal skeleton are naturally repaired through successive stepsinvolving specific cell types in a process collectively termed “bone regeneration”.Although complex, bone regeneration occurs through a series of well-orchestratedstages wherein endogenous bone stem cells play a central role. In most situations,bone regeneration is successful;however, there are instances when it fails andcreates non-healing injuries or fracture nonunion requiring surgical or therapeuticinterventions. Transplantation of adult or mesenchymal stem cells (MSCs) definedby the International Society for Cell and Gene Therapy (ISCT) as CD105+-CD90+CD73+CD45-CD34-CD14orCD11b-CD79αorCD19-HLA-DR- is beinginvestigated as an attractive therapy for bone regeneration throughout the world.MSCs isolated from adipose tissue, adipose-derived stem cells (ADSCs), aregaining increasing attention since this is the most abundant source of adult stemcells and the isolation process for ADSCs is straightforward. Currently, there isnot a single Food and Drug Administration (FDA) approved ADSCs product forbone regeneration. Although the safety of ADSCs is established from their usagein numerous clinical trials, the bone-forming potential of ADSCs and MSCs, ingeneral, is highly controversial. Growing evidence suggests that the ISCT definedphenotype may not represent bona fide osteoprogenitors. Transplantation of bothADSCs and the CD105- sub-population of ADSCs has been reported to induce bone regeneration. Most notably, cells expressing other markers such as CD146,AlphaV, CD200, PDPN, CD164, CXCR4, and PDGFRα have been shown torepresent osteogenic sub-population within ADSCs. Amongst other strategies toimprove the bone-forming ability of ADSCs, modulation of VEGF, TGF-β1 andBMP signaling pathways of ADSCs has shown promising results. The U.S. FDAreveals that 73% of Investigational New Drug applications for stem cell-basedproducts rely on CD105 expression as the “positive” marker for adult stem cells.A concerted effort involving the scientific community, clinicians, industries, andregulatory bodies to redefine ADSCs using powerful selection markers andstrategies to modulate signaling pathways of ADSCs will speed up thetherapeutic use of ADSCs for bone regeneration. | Quang Le Vedavathi Madhu Joseph M Hart Charles R Farber Eli R Zunder Abhijit S Dighe Quanjun Cui | 2021 | World Journal of Stem Cells2021，13，9： | 2 |
| 2 | Inactivation of hepatitis A virus (HAV) in fruits and vegetables by gamma irradiation显示文摘 | BIDAWID S FARBER J M SATTAR S A | 2000 | Int J Food Microbiol2000，57，12： | 1 |
| 3 | Accounting for the value of ecosystem services显示文摘 | Howarth R B Farber S | 2002 | Ecological Economics2002，41，3： | 1 |
| 4 | Arabinogalac- tan - folic acid - drug conjugate for targeted delivery and target - ac- tivated release of anticancer drugs to folate receptor - overexpress- ing cells 显示文摘 | PINHASSI R I ASSARAF Y G FARBER S | 2010 | Biomacromolecules2010，11，1： | 1 |
| 5 | Valuing ecosystem services显示文摘 | Liu S Costanza R Farber S | 2010 | Annals of the New York Academy of Sciences2010，1185，1： | 1 |
| 6 | Cha- racterizing the antigenic profile of the human trachea: implica- tions for tracheal transplantation显示文摘 | SHAARI C M FARBER D BRANDWEIN M S | 1998 | Head Neck1998，20，6： | 1 |
| 7 | Valuation and management of wetland ecosystems显示文摘 | Costanza R Farber S C Maxwell J | 1989 | Ecological Economics1989，1，33： | 1 |
| 8 | Arabinogalactan folic acid drug conjugate for targeted delivery and targe- tactivated release of anticaneer drugs to folate receptor- overexpressing cells显示文摘 | Pinhassi RI Assaraf YG Farber S | 2010 | Biomacromolecules2010，11，1： | 1 |
| 9 | Reducing costs and pa- tient morbidity in the enterally fed intensive care unit pa- tient显示文摘 | Farber M S Moses J Korn M | 2005 | JPEN J Parenter Enteral Nutr2005，29，1： | 1 |
| 10 | SAP HANA database:data management for modern business applications显示文摘 | Farber F Cha S K Primsch J | 2011 | SIGMOD Record2011，40，4： | 1 |
| 11 | Valuation and management of wetlands ecosystem servicees显示文摘 | Farber S C Maxewell J | 1989 | Ecological Economics1989，16，1： | 1 |
| 12 | Accounting for the value of ecosystem services 显示文摘 | Howarth R B Farber S | 2002 | Ecological Economics2002，41，3： | 1 |
| 13 | Marital quality and self-efficacy:influence on disease management among individuals with rheumatoid arthritis显示文摘 | Tewary S Farber N | 2014 | J Evidence-Based Social Work2014，11，3： | 1 |
| 14 | Myocardial ischemia: the pathogenesis of irreversible cell injury in ischemia显示文摘 | Farber JL Chien KR Mittnacht S Jr | 1981 | Am J Pathol1981，102，： | 1 |
| 15 | The pathogenesis of irreversible cell injury in isehemia显示文摘 | FARBER J L CHIEN K R MITTNACHT S J R | 1981 | Am J Pathol1981，102，： | 1 |
| 16 | A systematic investigation of cross-validation in GWR model estimation:empirical analysis and Monte Carlo simulations显示文摘 | Farber S Paez A | 2007 | J Geograph Syst2007，，9： | 1 |
| 17 | Chemotherapy in the treatment of leukemia and Wilms' tumor显示文摘 | Farber S | 1966 | JAMA1966，198，8： | 1 |
| 18 | Determi- ning pavement skid-resistance requirements at intersections and braking sites显示文摘 | FARBER E JANOFF M S CRISTINZIO S | 1974 | NCHRP Report1974，21，6： | 1 |
| 19 | Welfare Loss of Wtlands Disinteration:a Louisiana Study显示文摘 | FARBER S | 1996 | Contemporary Economic Policy1996，14，： | 1 |
| 20 | Mass spectrometric kinetic studies on several azido polymers 显示文摘 | Farber M Harris S P and Srivastava R D | 1984 | Combustion and Flame1984，55，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员